Currently, there are 38.19M common shares owned by the public and among those 26.64M shares have been available to trade.
The company’s stock has a 5-day price change of 2.14% and -44.68% over the past three months. OBIO shares are trading -28.50% year to date (YTD), with the 12-month market performance down to -39.28% lower. It has a 12-month low price of $2.49 and touched a high of $8.87 over the same period. OBIO has an average intraday trading volume of 57.78K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.19%, -30.34%, and -47.12% respectively.
Institutional ownership of Orchestra BioMed Holdings Inc (NASDAQ: OBIO) shares accounts for 50.22% of the company’s 38.19M shares outstanding.
It has a market capitalization of $109.58M and a beta (3y monthly) value of 0.82. The earnings-per-share (ttm) stands at -$1.66. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.44% over the week and 14.63% over the month.
Earnings per share for the fiscal year are expected to decrease by -18.17%, and 7.39% over the next financial year. EPS should grow at an annualized rate of -1.68% over the next five years, compared to -273.68% over the past 5-year period.
Looking at the support for the OBIO, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on March 20, 2025, with the firm’s price target at $12. Barclays coverage for the Orchestra BioMed Holdings Inc (OBIO) stock in a research note released on January 02, 2025 offered a Overweight rating with a price target of $16. H.C. Wainwright was of a view on August 22, 2024 that the stock is Buy, while B. Riley Securities gave the stock Buy rating on July 25, 2024, issuing a price target of $15. Jefferies on their part issued Buy rating on January 19, 2024.
